What is the significance of pT0 at cystectomy?
| Autor: | Suril Patel, Muhammed Sohail, Rajendra Persad, Matthew R. Hotston |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Urology Disease Cystectomy Quality of life Internal medicine medicine Humans Neoplasm Invasiveness Stage (cooking) Neoadjuvant therapy Neoplasm Staging Chemotherapy Bladder cancer business.industry Muscle invasive Prognosis medicine.disease Neoadjuvant Therapy Treatment Outcome Urinary Bladder Neoplasms Lymphatic Metastasis Female Surgery business |
| Zdroj: | Surgical Oncology. 15:65-69 |
| ISSN: | 0960-7404 |
| DOI: | 10.1016/j.suronc.2006.07.005 |
| Popis: | Summary The current treatment for muscle invasive bladder cancer is radical cystectomy. However, this approach leads to significant changes in the patient's quality of life, as well as potential treatment failure. And so, with the introduction of alternative and neoadjuvant therapies available, the presence of pT0 tumour at cystectomy confers a number of issues. The variability in numbers of pT0 tumours at cystectomy highlights the importance of adequate clinical staging, as well as the increasing successful use of neoadjuvant chemotherapy. Although current literature is limited, patients with prior clinical stage of muscle-invasive but node-negative disease are likely to demonstrate the most improvement in survivability if they subsequently develop pT0 at cystectomy. This review also highlights the importance of response to chemotherapy as an indicator of subsequent prognosis. With increasing numbers of pT0 tumours seen at radical cystectomy, it is suggested that more conservative measures, such as re-staging following neoadjuvant chemotherapy and even ‘selective bladder preservation' treatment, may be the future for the management of muscle invasive bladder cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect